Valeant completes $475 mln buy of PE-backed PreCision Dermatology

Canadian specialty pharmaceutical company Valeant Pharmaceuticals International Inc (TSX: VRX) has completed its previously announced purchase of PreCision Dermatology Inc, a developer and marketer of dermatology products. As reported by Reuters in February, the deal was valued at $475 million. Formed in 2010 as the result of the spin-out of Onset Therapeutics, a subsidiary of Collegium Pharmaceutical Inc, the Cumberland, Rhode Island-based PreCision was backed by U.S. private equity firms Boston Millennia Partners, Essex Woodlands, Frazier Healthcare and Westfield Capital Management.

PRESS RELEASE

Valeant Pharmaceuticals Completes Acquisition Of PreCision Dermatology

LAVAL, Quebec, July 8, 2014 /PRNewswire/ — Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced it has completed the previously announced acquisition of PreCision Dermatology, Inc. PreCision develops and markets high quality dermatology products with leading products such as Locoid, Hylatopic, and Clindagel.

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology and branded generics. More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

Contact Information:

Laurie W. Little
949-461-6002
laurie.little@valeant.com

SOURCE Valeant Pharmaceuticals International, Inc.

Photo courtesy of Shutterstock